文献速递肾小球疾病

Pegcetacoplan治疗C3肾小球病的2期研究安全性及疗效

Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.
PubMed 文献 · Kidney Int Rep · 2023-08-25

这项开放标签2期48周研究评估皮下注射Pegcetacoplan在补体介导肾小球疾病中的初步疗效与安全性。C3G队列意向治疗人群(n=7)48周蛋白尿平均降低50.9%,符合方案人群(n=4)降低65.4%,eGFR稳定,血清C3升高6倍,sC5b-9降低57.3%,未报告脑膜炎或脓毒症,无严重治疗相关不良事件。

要点

  • C3G队列ITT人群48周蛋白尿平均降低50.9%,PP人群降低65.4%。
  • 48周内平均eGFR稳定,平均血清白蛋白恢复正常。
  • 常见不良事件为上呼吸道感染、注射部位红斑、恶心和头痛。

核心结论

  • Pegcetacoplan可能为C3G提供治疗获益,并在所研究的4种肾小球疾病中具有良好安全性特征。

研究设计与样本

  • 开放标签、2期、48周研究,评估皮下注射Pegcetacoplan用于补体介导肾小球疾病患者。
  • 主要终点为蛋白尿降低,以24小时尿蛋白-肌酐比值衡量;次要终点包括缓解状态、eGFR变化和药效学生物标志物。

主要发现

  • C3G队列ITT人群(n=7)从基线至第48周蛋白尿平均降低50.9%,PP人群(n=4)平均降低65.4%。
  • C3G队列平均血清白蛋白恢复正常,平均eGFR在48周内稳定。
  • 第48周平均血清C3水平升高6倍,平均可溶性C5b-9水平降低57.3%。
  • 最常见不良事件为上呼吸道感染、注射部位红斑、恶心和头痛。
  • 未报告脑膜炎或脓毒症病例,未观察到严重治疗相关不良事件。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dysregulated complement activation is likely the primary driver of disease in C3 glomerulopathy (C3G) and contributes to other complement-mediated diseases, including immunoglobulin A nephropathy (IgAN), lupus nephritis (LN), and primary membranous nephropathy (PMN). No complement inhibitors are proven to halt disease progression in these diseases. Pegcetacoplan, a targeted C3 and C3b inhibitor, may mitigate complement-mediated kidney damage in C3G and other glomerular diseases in which complement may have a pathogenic role. METHODS: This open-label, phase 2, 48-week study evaluated the preliminary efficacy and safety of subcutaneous pegcetacoplan for patients with complement-mediated glomerular diseases. The primary end point was proteinuria reduction, measured as 24-hour urine protein-to-creatinine ratio. Secondary end points included remission status, changes in estimated glomerular filtration rate (eGFR), and pharmacodynamic biomarkers. Treatment-emergent adverse events (TEAEs) were monitored. RESULTS: Efficacy results for the C3G cohort are reported herein, along with safety results for the study population. In the C3G cohort, mean proteinuria reduction from baseline to week 48 was 50.9% in the intent-to-treat (ITT) population (n = 7) and 65.4% in the per-protocol (PP) population (n = 4). Mean serum albumin normalized and mean eGFR was stable over 48 weeks. Mean serum C3 levels increased 6-fold and mean soluble C5b-9 levels decreased by 57.3% at week 48. The most common adverse events (AEs) were upper respiratory tract infection, injection site erythema, nausea, and headache. No meningitis or sepsis cases were reported, and no serious treatment-related AEs were observed. CONCLUSION: Pegcetacoplan may provide therapeutic benefit for C3G and has a favorable safety profile across the 4 glomerular diseases studied.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Dixon BP, Greenbaum LA, Huang L, et al. Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney Int Rep. 2023. PMID: 38025230. doi:10.1016/j.ekir.2023.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。